PYQUVI (deflazacort) by PTC Therapeutics is corticosteroid hormone receptor agonists [moa]. Approved for duchenne muscular dystrophy (dmd) in patients 2 years of age, older (). First approved in 2025.
Drug data last refreshed 3d ago
Corticosteroid Hormone Receptor Agonists
Corticosteroid
A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)
Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers
A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics
An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort
Worked on PYQUVI at PTC Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.